Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Income from Continuing Operations (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Income from Continuing Operations for 10 consecutive years, with 122556000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations fell 128.58% to 122556000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 569000000.0 through Dec 2025, down 8028.57% year-over-year, with the annual reading at 569000000.0 for FY2025, 8028.57% down from the prior year.
  • Income from Continuing Operations for Q4 2025 was 122556000.0 at Ultragenyx Pharmaceutical, up from 180413000.0 in the prior quarter.
  • The five-year high for Income from Continuing Operations was 485449000.0 in Q4 2023, with the low at 245106000.0 in Q3 2022.
  • Average Income from Continuing Operations over 5 years is 87055250.0, with a median of 143610500.0 recorded in 2021.
  • The sharpest move saw Income from Continuing Operations plummeted 583.62% in 2021, then surged 412.87% in 2023.
  • Over 5 years, Income from Continuing Operations stood at 124791000.0 in 2021, then decreased by 24.34% to 155159000.0 in 2022, then soared by 412.87% to 485449000.0 in 2023, then fell by 11.67% to 428798000.0 in 2024, then tumbled by 128.58% to 122556000.0 in 2025.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 122556000.0, 180413000.0, and 114951000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.